Aim To assess the long-term clinical benefits of early combination treatment with vildagliptin-metformin vs. standardof-care, metformin monotherapy in the ongoing VERIFY study.
Introduction
There is debate about the optimum early pharmacological treatment of diabetes, although most authorities recommend metformin [1] . Beyond metformin it is usual to add a second therapy, but often this intensification occurs late, long after good glycaemic control is lost [2] . Second line agents include dipeptidyl peptidase-4 (DPP-4) inhibitors, which are good candidates for early combination therapy [1] . DPP-4 inhibitors improve glucose homeostasis synergistically with metformin even in mild hyperglycaemia, without the adverse effects of weight gain and hypoglycaemia [3, 4] .
VERIFY (Vildagliptin Efficacy in combination with metfoRmIn For earlY treatment of Type 2 diabetes) is an ongoing, 5-year, multinational, multi-ethnic study being conducted in 254 centres across 34 countries (Appendix :  Table A1 ). We aimed to investigate, for the first time, the long-term benefits of early treatment intensification with a DPP-4 inhibitor (vildagliptin)-metformin combination over standard-of-care metformin monotherapy in maintaining durable glycaemic control in people with newly diagnosed Type 2 diabetes.
In contrast to many cardiovascular outcome studies, we aimed to recruit a population reflecting the typical characteristics of newly diagnosed people living with diabetes worldwide.
Methods

Study design
The study design has been described in detail elsewhere [5] . Briefly, the VERIFY trial (NCT01528254) is an ongoing randomized, double-blind, parallel-group study consisting of a screening visit, a 3-week metformin-alone run-in period, and a 5-year treatment period during which the treatment is consecutively intensified, when clinically indicated at the investigators' discretion. Durability of glycaemic control, time to insulin initiation, changes in b-cell function and insulin sensitivity have been assessed over time.
The study protocol was approved by the Institutional Review Boards, Independent Ethics Committees and Competent Health Authorities in accordance with European Community Directive 2001/20/EC or as per national and international regulatory requirements in participating countries.
Study population
Participants aged 18-70 years, newly diagnosed with Type 2 diabetes (≤24 months) as per local diagnostic criteria, having centrally confirmed HbA 1c levels between 48 mmol/mol (6.5%) and 58 mmol/mol (7.5%), and BMI 22-40 kg/m 2 ,
were included in the study [5] . Individuals undergoing antidiabetes treatment (except for short-term metformin) within 3 months prior to screening, or using any weight-loss medications were excluded, as were pregnant or breastfeeding women, and those with chronic liver disease or ongoing congestive heart failure [New York Heart Association (NYHA) III or IV].
Study assessments
Baseline measurements were obtained at the screening visit, or at the next visit prior to initiation of metformin uptitration. The primary efficacy assessments include HbA 1c measurements to determine the time to initial treatment failure and the rate of loss in glycaemic control over time.
Participants visit the study site every 13 weeks for 5 years to comply with the study procedures [5] . Laboratory samples are collected at each visit and analysed. Vital signs, electrocardiogram, body weight, haematology and biochemistry, fasting lipid profile and triglycerides, liver and renal function tests, urinalysis and adverse events are the key safety assessments. Major adverse cardiovascular events are independently adjudicated (exploratory endpoint) and an independent data safety committee monitors an unblinded periodic review of all safety data.
In a large subpopulation (n=462), standardized and locally adapted, annual meal-tests are performed for assessment of plasma glucose levels, insulin, and C-peptide concentrations. Indices of b-cell function (insulin secretion rate relative to glucose and homeostasis model assessment of b-cell function (HOMA-ß)), insulin sensitivity (oral glucose sensitivity index), and insulin resistance (HOMA-% sensitivity) are calculated [6, 7] .
Statistical analysis
Blinded baseline demographics and key glycaemic variables were analysed descriptively and summarized for all randomized participants. Categorical variables including age, gender and BMI were summarized with frequency and percentage, whereas continuous variables including duration of disease and HbA 1c were summarized with mean AESD.
Results
Recruitment of participants
Recruitment for the VERIFY trial started in March 2012 and randomization was completed in April 2014. A total of 2001 people, newly diagnosed with mild hyperglycaemia, were randomized out of the 4524 screened. The major reason for screening failure was an HbA 1c value outside the protocol-defined, centrally assessed range of 48-58 mmol/mol (6.5-7.5%). A total of 66 participants were classified as run-in failures because of metforminintolerance prior to up-titration to the lowest targeted dose of 1000 mg/day. Details of participants' dispositions are shown in Figure 1 .
What's new?
• The VERIFY study is the first study to assess the longterm clinical benefits of early combination treatment with a dipeptidyl peptidase-4 inhibitor (vildagliptin)-metformin vs. standard-of-care metformin monotherapy in people newly diagnosed with Type 2 diabetes.
• This report describes the baseline characteristics of a newly diagnosed population with Type 2 diabetes from a diverse geographical and ethnic background, demonstrating a classic profile of presence of early insulin resistance associated with elevated BMI as a surrogate for obesity.
• The study anticipates generating unique evidence on the progression of b-cell function, insulin resistance, early complications of diabetes, and effect on health status upon treatment with early vildagliptin-metformin combination.
The geographical distribution of participants enrolled for this trial was: Europe (52.4%), Latin America (26.8%), Asia (17.2%), South Africa (3.1%) and Australia (0.5%).
Baseline characteristics
Overall demographics and baseline characteristics of participants are presented in Table 1 .
The median (interquartile range) age of participants was 55 (48, 62) years, baseline HbA 1c 52AE3 mmol/mol (corresponding to 6.9AE0.3%), fasting plasma glucose 7.5AE1.5 mmol/l, and median (interquartile range) duration of diabetes 3.4 (0.9,10.2) months. Overall, men and women were often enrolled equally in the study despite some country-level differences. The mean baseline GFR was 87.4AE18.5 ml/min/ 1.73m 2 . Overall, 14.5% of the study population were smoking at baseline. Presence of early microvascular complications were reported in 8% of the participants enrolled. At baseline the median (interquartile range) of fasting insulin was 109 (75-160) mU/l, and HOMA-ß and HOMA-% sensitivity values were 84% (60, 116) and 46% (31, 68), respectively. In the subset of participants (n=462) undertaking meal-tests, 2-hour plasma glucose values were 9.3AE2.8 mmol/l, insulin secretion rate relative to glucose was 28AE12 pmol/min/ m 2 /mmol/l, and oral glucose sensitivity index value was 353AE57 ml/min/m 2 . Table 2 shows the variability of the meal-test measurements by geographic distribution.
Discussion
The VERIFY study cohort explores a newly diagnosed population with Type 2 diabetes with mild hyperglycaemia who have the potential for preservation of their b-cell function, and for achieving a long-term durable response to early therapy.
One principal goal of treating newly diagnosed drug-naive individuals is to achieve glycaemic control approaching normoglycaemia [8] . This trial explores the concept that optimization of therapy, in this case with an early vildagliptin-metformin combination, could overcome b-cell functional deterioration and thereby extend the durability of treatment over time.
Previous intervention studies on initial combination therapy have recruited participants with baseline HbA 1c levels ≥64 mmol/mol (≥8.0%) [9] [10] [11] [12] [13] [14] [15] . Additionally, A Diabetes Outcome Progression Trial (ADOPT) [16] and Diabetes Prevention Program (DPP) [17] reported limited baseline variables with populations having a higher range of baseline HbA 1c . By contrast, the VERIFY trial will assess the durability of glycaemic response in individuals recruited at, or close to, diagnosis and with near-normal HbA 1c . The data show a 16.5% median decrease in b-cell function but marked reduction in insulin sensitivity to 46%. Insulin resistance is the reciprocal of the sensitivity, so those recruited have an insulin resistance that is double that found in people without diabetes.
Data obtained from the meal-test substudy are reflective of regional variations observed in plasma glucose, C-peptide, and insulin concentrations, which may prove important in the subgroup analysis of b-cell failure. Previously published data [18, 19] 
Long-term clinical trials normally pose a big challenge with low study participant retention. Evaluating the durability of treatment prospectively necessitates retention throughout the duration of the study. The VERIFY trial has an active retention programme, tailored to the needs of individuals, but over time the study is also carrying out innovative, relational real-time data monitoring to improve the retention rates.
The presence of baseline microvascular complications, including proliferative and non-proliferative retinopathy, nephropathy, neuropathy, and foot ulcer conditions, demonstrates the asymptomatic nature of Type 2 diabetes and early onset of foundation for its complications, emphasizing the importance of early treatment interventions to prevent or slow down the disease progression prior to advent of further diabetic complications.
The major strength of the VERIFY trial is the selection of a geographically distributed diverse, multi-ethnic population and long-term duration of 5 years for all the participants, ensuring the generalizability of the trial results and providing guidance in clinical decision making for the increasing number of people with newly diagnosed Type 2 diabetes. The enrolled participants display a classic profile of presence of early insulin resistance associated with elevated BMI as a surrogate for obesity. The study anticipates the generation of unique evidence for many geographical areas with limited or no prior epidemiological or other data on b-cell function, insulin resistance, early complications of diabetes, and effect on health status upon treatment with a DPP-4 inhibitor-metformin combination. The study is currently underway and will report in 2019. 
